Appendix C

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Everolimus for the prevention of organ rejection in allogeneic liver transplantation [ID559]

Provisional matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Manufacturers/sponsors • Novartis Pharmaceuticals UK (everolimus) Patient/carer groups • Addenbrookes Liver Transplant Association • Afiya Trust • Black Health Agency • British Liver Trust • Counsel and Care • Equalities National Council • Muslim Council of Great Britain • Muslim Health Network • South Asian Health Foundation • Specialised Healthcare Alliance • Transplant Support Network Professional groups • Association of Surgeons of Great Britain and Ireland • British Association for Services to the Elderly • British Association for the Study of the Liver • British Association for the Study of the Liver Nurses Forum • British Geriatrics Society • British Liver Nurses Forum • British Society of Gastroenterology • British Transplantation Society • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians	General • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicine's Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium Possible comparator manufacturer(s) • Actavis UK (prednisolone, azathioprine, mycophenolate mofetil) • Arrow Generics (prednisolone, azathioprine) • Aspen (azathioprine) • Astellas Pharma (tacrolimus) • Dexcel Pharma (ciclosporin, tacrolimus) • Focus Pharmaceuticals (azathioprine) • Mylan UK (tacrolimus, azathioprine, ciclosporin) • Novartis Pharmaceuticals (mycophenolic acid, ciclosporin) • Pfizer (prednisolone) • Roche Products (mycophenolate

Consultees	**Commentators (no right to submit or appeal)**
• Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • United Kingdom Clinical Pharmacy Association <u>Others</u> • Department of Health • Lancashire PCT Cluster • Merseyside PCT Cluster • Welsh Government	mofetil) • Sandoz (tacrolimus, mycophenolate mofetil) • Teva UK (prednisolone, mycophenolate mofetil, tacrolimus, azathioprine) • Zentiva UK (mycophenolate mofetil, prednisolone) <u>Relevant research groups</u> • Foundation for Liver Research • MRC Clinical Trials Unit • National Institute of Health Research • Research Institute for the Care of Older People <u>Evidence Review Group</u> • Evidence Review Group tbc • National Institute for Health Research Health Technology Assessment Programme <u>Associated Guideline Groups</u> • National Clinical Guideline Centre <u>Associated Public Health Groups</u> • tbc

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

[1] Non manufacturer consultees are invited to submit statements relevant to the group they are representing.